Start with its own history
At 65.36×, ABMD is 17.1% below its 10-observation annual average. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.

Current valuation, historical context, and peer comparisons.
Current P/E ratio
65.36×
17.1% belowthe 10-year annual average
Price and EPS in quote currency. Calculation details
Investors are paying 65.36 for every 1 of reported earnings per share.
Annual period-end data · 25 observations
| Period end | P/E | Change |
|---|---|---|
| Mar 31, 2022 | 110.41× | +73.2% |
| Mar 31, 2021 | 63.75× | +97.2% |
| Mar 31, 2020 | 32.33× | -32.8% |
| Mar 31, 2019 | 48.14× | -58.0% |
| Mar 31, 2018 | 114.56× | +10.7% |
| Mar 31, 2017 | 103.47× | -1.8% |
| Mar 31, 2016 | 105.34× | +312.1% |
| Mar 31, 2015 | 25.56× | -81.3% |
| Period end | P/E | Change |
|---|---|---|
| Mar 31, 2014 | 137.05× | +184.6% |
| Mar 31, 2013 | 48.16× | -91.3% |
| Mar 31, 2012 | 554.75× | N/M |
| Mar 31, 2011 | N/M | N/M |
| Mar 31, 2010 | N/M | N/M |
| Mar 31, 2009 | N/M | N/M |
| Mar 31, 2008 | N/M | N/M |
| Mar 31, 2007 | N/M | N/M |
| Mar 31, 2006 | N/M | N/M |
| Mar 31, 2005 | N/M | N/M |
| Mar 31, 2004 | N/M | N/M |
| Mar 31, 2003 | N/M | N/M |
| Mar 31, 2002 | N/M | N/M |
| Mar 31, 2001 | N/M | N/M |
| Mar 31, 2000 | N/M | N/M |
| Mar 31, 1999 | N/M | N/M |
| Mar 31, 1998 | N/M | N/M |
Change is relative to the preceding observation. N/M values are excluded from averages.
Company P/E vs. peer trailing-12-month ratios
| Company | P/E ratio |
|---|---|
ABMD This stockAbiomed, Inc. | 65.36× |
SWAVShockWave Medical, Inc. | 83.48× |
NUVANuVasive, Inc. | 50.96× |
DWRKFDrägerwerk AG & Co. KGaA | 12.94× |
NHNKFNihon Kohden Corporation | 20.51× |
NTUSNatus Medical Incorporated | 84.51× |
CSSPFNIOX Group Plc | 35.93× |
EKDHFEKF Diagnostics Holdings plc | 41.38× |
CKMTFCarmat S.A. | N/M |
Peers are selected by the data provider. Business models and earnings definitions can differ.
Put the numbers in context
At 65.36×, ABMD is 17.1% below its 10-observation annual average. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.
The median of the 7 positive peer ratios above is 41.38×. Check growth, margins, debt, and earnings quality before interpreting the gap. A faster-growing business may justify a higher multiple.
One-off gains can temporarily lower P/E; unusual charges can raise it. Reported earnings and forward estimates answer different questions. Pair this view with return on equity and liquidity for a fuller picture.
Keep your research connected
Pull historical P/E into Excel or Google Sheets with Wisesheets. Build your own comparisons alongside the rest of your financial model.
Explore Wisesheets=WISE("ABMD", "PE Ratio", "LQ")Share price 381.02 ÷ EPS 5.83 = 65.36×. Data is supplied by Financial Modeling Prep through Wisesheets. Quote feed updated Not supplied; this is not a real-time trading quote.
Annual and quarterly P/E observations are provided separately from the current quote. Averages use the latest 3, 5, or 10 annual observations, excluding missing and nonpositive ratios. Pre-IPO observations are omitted. These are period-end observations, not daily averages.
The current quote feed does not specify the exact EPS filing-period end or whether EPS is basic or diluted. We do not label it as forward P/E. Peer ratios are explicitly trailing-12-month (TTM) values. Historical observations do not include independently verified price and EPS inputs. Sources may update on different schedules; rounded inputs can produce small calculation differences. Historical comparisons describe past pricing, not an estimate of fair value.
The essentials behind the numbers.